Targeting ecto-5'-nucleotidase : A comprehensive review into small molecule inhibitors and expression modulators
Copyright © 2022 Elsevier Masson SAS. All rights reserved..
The purinergic signaling has drawn attention from academia and more recently from pharmaceutical industries as a potential therapeutic route for cancer treatment, since ATP may act as chemotactic agent and possess in vitro antineoplastic activity. On the other way, adenosine, produced in extracellular medium by ecto-5'-NT, acts as immunosuppressor and is related to neoangiogenesis, vasculogenesis and evasion to the immune system. Consequently, inhibitors of ecto-5'-NT may prevent tumor progression, reducing adenosine concentrations, preventing escape from the host's immune system and slowing cancer's growth. This review aims to highlight important biochemical and structural features of ecto-5'NT, highlight its expression profile in normal and cancer cell lines detailing compounds which may act as expression regulators and to review the several classes of ecto-5'NT inhibitors developed in the past 12 years, in order to build a general structure-activity relationship model to guide further compound design.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:247 |
|---|---|
| Enthalten in: |
European journal of medicinal chemistry - 247(2023) vom: 05. Feb., Seite 115052 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
das Neves, Gustavo Machado [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.01.2023 Date Revised 17.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejmech.2022.115052 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351104194 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351104194 | ||
| 003 | DE-627 | ||
| 005 | 20231226050534.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejmech.2022.115052 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1170.xml |
| 035 | |a (DE-627)NLM351104194 | ||
| 035 | |a (NLM)36599229 | ||
| 035 | |a (PII)S0223-5234(22)00954-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a das Neves, Gustavo Machado |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting ecto-5'-nucleotidase |b A comprehensive review into small molecule inhibitors and expression modulators |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2023 | ||
| 500 | |a Date Revised 17.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a The purinergic signaling has drawn attention from academia and more recently from pharmaceutical industries as a potential therapeutic route for cancer treatment, since ATP may act as chemotactic agent and possess in vitro antineoplastic activity. On the other way, adenosine, produced in extracellular medium by ecto-5'-NT, acts as immunosuppressor and is related to neoangiogenesis, vasculogenesis and evasion to the immune system. Consequently, inhibitors of ecto-5'-NT may prevent tumor progression, reducing adenosine concentrations, preventing escape from the host's immune system and slowing cancer's growth. This review aims to highlight important biochemical and structural features of ecto-5'NT, highlight its expression profile in normal and cancer cell lines detailing compounds which may act as expression regulators and to review the several classes of ecto-5'NT inhibitors developed in the past 12 years, in order to build a general structure-activity relationship model to guide further compound design | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Ecto-5′-nucleotidase | |
| 650 | 4 | |a Expression modulation | |
| 650 | 4 | |a Medicinal chemistry | |
| 650 | 4 | |a Purinergic signaling | |
| 650 | 4 | |a Small molecule inhibitors | |
| 650 | 4 | |a cd73 | |
| 650 | 7 | |a 5'-Nucleotidase |2 NLM | |
| 650 | 7 | |a EC 3.1.3.5 |2 NLM | |
| 650 | 7 | |a Adenosine |2 NLM | |
| 650 | 7 | |a K72T3FS567 |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Kagami, Luciano Porto |e verfasserin |4 aut | |
| 700 | 1 | |a Battastini, Ana Maria Oliveira |e verfasserin |4 aut | |
| 700 | 1 | |a Figueiró, Fabrício |e verfasserin |4 aut | |
| 700 | 1 | |a Eifler-Lima, Vera Lucia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of medicinal chemistry |d 1994 |g 247(2023) vom: 05. Feb., Seite 115052 |w (DE-627)NLM106608835 |x 1768-3254 |7 nnns |
| 773 | 1 | 8 | |g volume:247 |g year:2023 |g day:05 |g month:02 |g pages:115052 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejmech.2022.115052 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 247 |j 2023 |b 05 |c 02 |h 115052 | ||